VRTX Dividend History & Description — Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor). When considering the Vertex Pharmaceuticals, Inc. stock dividend history, we have taken known splits into account, such that the VRTX dividend history is presented on a split-adjusted ("apples to apples") basis. Vertex Pharmaceuticals, Inc. dividend history is presented both in graphical/chart form, and as a VRTX dividend history data table along the right-hand column.